-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec Content Team Editor On February 15, 2022, Ambrx Biopharma announced that its IND application for the antibody-drug conjugate (ADC) ARX305 has been approved by the US FDA
.
ARX305 is a CD70-targeted ADC for the treatment of a broad range of solid and hematological tumors, including renal cell carcinoma (RCC)
.
ARX305 targets CD70-expressing tumor cells
.
CD70 is highly expressed in a variety of solid tumors and hematological cancers, including renal cell carcinoma, nasopharyngeal carcinoma, multiple myeloma, non-Hodgkin lymphoma, and acute myeloid leukemia
.
In a variety of tumor cells and models, ARX305 shows good in vitro and in vivo effects, and is expected to directly kill CD70-overexpressing tumors and improve the tumor microenvironment
.
In addition, Ambrx entered into a partnership in 2019 to license the development and commercialization rights of ARX305 in China to NovoCodex Pharmaceuticals
.
FDA-approved clinical study ARX305-01 is a first-in-human, multicenter, open-label, dose-escalation and dose-expansion Phase 1 clinical trial evaluating clear cell renal cells that are resistant or refractory to prior standard therapy Safety, pharmacokinetics and preliminary antitumor activity of ARX305 in adult patients with clear cell renal cell carcinoma
.
▲Amboo Bio product pipeline (Image source: Amb Bio’s official website) “I am very satisfied with the milestones we have achieved in the development of antibody conjugated drugs, which is our third ADC project to reach this stage of development
.
” Chairman of the Board of Amb Bio Bio "The entry of ARX305 into clinical trials targeting different tumors expressing CD70 strengthens our confidence in the broad application of the platform," said Dr.
Tian Feng, President and CEO of , "ARX305
.
" Reference: [1] Ambrx Biopharma Inc.
Announces Submission of IND Application for ARX305 with the US FDA.
Retrieved February 15, 2022, from https:// Disclaimer: WuXi AppTec content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
.
This article is also not a treatment plan recommendation
.
For guidance on treatment options, please visit a regular hospital
.
.
ARX305 is a CD70-targeted ADC for the treatment of a broad range of solid and hematological tumors, including renal cell carcinoma (RCC)
.
ARX305 targets CD70-expressing tumor cells
.
CD70 is highly expressed in a variety of solid tumors and hematological cancers, including renal cell carcinoma, nasopharyngeal carcinoma, multiple myeloma, non-Hodgkin lymphoma, and acute myeloid leukemia
.
In a variety of tumor cells and models, ARX305 shows good in vitro and in vivo effects, and is expected to directly kill CD70-overexpressing tumors and improve the tumor microenvironment
.
In addition, Ambrx entered into a partnership in 2019 to license the development and commercialization rights of ARX305 in China to NovoCodex Pharmaceuticals
.
FDA-approved clinical study ARX305-01 is a first-in-human, multicenter, open-label, dose-escalation and dose-expansion Phase 1 clinical trial evaluating clear cell renal cells that are resistant or refractory to prior standard therapy Safety, pharmacokinetics and preliminary antitumor activity of ARX305 in adult patients with clear cell renal cell carcinoma
.
▲Amboo Bio product pipeline (Image source: Amb Bio’s official website) “I am very satisfied with the milestones we have achieved in the development of antibody conjugated drugs, which is our third ADC project to reach this stage of development
.
” Chairman of the Board of Amb Bio Bio "The entry of ARX305 into clinical trials targeting different tumors expressing CD70 strengthens our confidence in the broad application of the platform," said Dr.
Tian Feng, President and CEO of , "ARX305
.
" Reference: [1] Ambrx Biopharma Inc.
Announces Submission of IND Application for ARX305 with the US FDA.
Retrieved February 15, 2022, from https:// Disclaimer: WuXi AppTec content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
.
This article is also not a treatment plan recommendation
.
For guidance on treatment options, please visit a regular hospital
.
